Adalimumab and infliximab are equally efficient in achieving sustained remission in ulcerative colitis but infliximab is superior in severe disease—a retrospective observational study
Adalimumab and infliximab achieved similar rates of long-term remission in bio-naive patients with ulcerative colitis. However, infliximab was superior in induction of remission and in patients with severe disease.
Authors
- Jenny Gunnarsson
- Sofia Ågren
- Georgios Mavroudis (ORCID: https://orcid.org/0000-0001-9652-5474)
- Anders Lasson
- Börje Jonefjäll
- Thomas de Lange
Institutions
- Sahlgrenska University Hospital (SE)
- Södra Älvsborg Hospital (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Scandinavian Journal of Gastroenterology
- Published
- 2026-02-22
- DOI
- https://doi.org/10.1080/00365521.2026.2633732
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00